Mode
Text Size
Log in / Sign up

Open mitral valve repair and V-Clamp TEER offer distinct outcomes for canine mitral valve diseaseNew framework helps doctors choose heart surgery for dogs

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider a selection framework based on anatomy and experience when choosing between OMVR and V-Clamp TEER.

This narrative review evaluates the clinical outcomes and feasibility of open mitral valve repair (OMVR) compared to transcatheter edge-to-edge repair (TEER) using the V-Clamp device in dogs with advanced myxomatous mitral valve disease (MMVD). The review synthesizes data on surgical survival, procedural feasibility, and long-term outcomes.

OMVR is associated with a surgical survival rate exceeding 99% in a population of more than 1,000 dogs. In contrast, V-Clamp TEER demonstrates an acute procedural feasibility of 96-97% and a two-year all-cause survival rate of 67%. The authors note that direct numerical comparisons between these two modalities require caution due to differences in evidence maturity and the specific outcome metrics reported across studies.

Several limitations are noted, including variations in outcomes across centers due to selection, anatomy, and the learning curve. The review suggests a selection framework to guide clinical decisions between OMVR, V-Clamp, and medical management based on ACVIM stage, anatomy, size, comorbidity, and center experience. This framework aims to address the complexities of managing advanced MMVD in canine patients.

How this fits prior evidence

This narrative review addresses a gap in clinical decision-making for advanced myxomatous mitral valve disease. While prior coverage noted that omics integration provides a theoretical basis for new diagnostic markers and targeted therapies in mitral valve disease, this review focuses on the practical clinical comparison between OMVR and V-Clamp TEER. It provides a selection framework to guide treatment based on specific patient factors like ACVIM stage and anatomy.

When a dog suffers from advanced mitral valve disease, the choice of treatment can be difficult. Owners and doctors must decide between traditional open surgery and newer, less invasive procedures. This review looks at the differences between open mitral valve repair and a newer device called V-Clamp TEER.

Open surgery has shown a survival rate of over 99% for more than 1,000 dogs. In contrast, the V-Clamp device showed a 96% to 97% success rate for the initial procedure, but a 67% survival rate at the two-year mark. Because these two methods use different types of data, comparing them directly can be tricky.

To help make the best choice, experts suggest a new selection framework. This system looks at the dog's heart stage, their physical size, and the specific anatomy of the heart. It also considers the dog's other health issues and how much experience the local clinic has with these specific procedures.

What this means for you:
A new framework helps doctors choose between open heart surgery and less invasive options based on the dog's specific needs.

Common questions

What is the survival rate for open heart surgery in dogs?

Open mitral valve repair has shown a surgical survival rate exceeding 99% for more than 1,000 dogs. This high success rate makes it a well-established option for treating advanced heart disease in dogs.

How does the V-Clamp device compare to open surgery?

The V-Clamp device showed a 96% to 97% success rate for the initial procedure. However, its two-year all-cause survival rate was 67%. Because these two methods use different types of data, it is hard to compare them directly.

How do doctors decide which heart procedure is best?

Doctors can use a selection framework to decide. This looks at the dog's heart stage, size, anatomy, and other health issues. It also considers the specific experience level of the medical center performing the procedure.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease in dogs, and progression to congestive heart failure (CHF) and cardiac death remains common despite optimal medical management. Two surgical interventions are now clinically available for dogs with advanced MMVD: open mitral valve repair (OMVR) under cardiopulmonary bypass and transcatheter edge-to-edge repair (TEER) using the canine V-Clamp device. This narrative review synthesizes the contemporary literature on both techniques and proposes a framework to guide patient selection. OMVR has more than a decade of clinical experience and a published outcome base of more than 1,000 dogs, with surgical survival rates exceeding 99% across all clinical stages and long-term mortality risk modulated by age, body weight, breed, and pulmonary vascular status. V-Clamp TEER has emerged since 2020 with multiple published clinical cohorts demonstrating high acute procedural feasibility (96–97% in the largest series) and, most recently, sustained one-year hemodynamic and remodeling improvements with two-year all-cause survival of 67% at the leading reporting center; outcomes vary across centers, reflecting the interacting influence of patient selection, anatomic eligibility, and operator learning curve. Because the two techniques differ in evidence maturity and in the outcome metrics reported, direct numerical comparison between them requires caution. OMVR achieves more complete mitral regurgitation (MR) reduction, while V-Clamp produces a less invasive double-orifice repair with intermediate hemodynamic effect that may partially regress in the presence of significant residual MR. A proposed selection framework integrates ACVIM stage, mitral valve anatomy, body size, comorbidity burden, and center experience to guide decisions among OMVR, V-Clamp, and continued medical management. Honest owner counseling that includes center-specific experience and the limits of each option remains a clinical priority as the field evolves.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.